(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 37.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.28%.
Karyopharm Therapeutics's revenue in 2026 is $142,530,000.On average, 8 Wall Street analysts forecast KPTI's revenue for 2026 to be $2,554,903,260, with the lowest KPTI revenue forecast at $2,195,641,303, and the highest KPTI revenue forecast at $2,904,446,218. On average, 5 Wall Street analysts forecast KPTI's revenue for 2027 to be $4,265,447,140, with the lowest KPTI revenue forecast at $3,163,619,533, and the highest KPTI revenue forecast at $6,209,588,022.
In 2028, KPTI is forecast to generate $6,423,576,515 in revenue, with the lowest revenue forecast at $3,786,317,525 and the highest revenue forecast at $9,584,979,435.